Compare Lamb Weston Holdings Inc (LW) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Nuvalent Inc — how do they compare? Lamb Weston Holdings Inc trades at $46.42 (market cap $6.43B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 3.26% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| LW | NUVL | |
|---|---|---|
Market Cap | $6.43B | $9.81B |
Sector | Consumer Staples | Technology |
52-Week High | $66.57 | $123.96 |
52-Week Low | $38.48 | $72.16 |
Enterprise Value | $10.40B | $8.52B |
Dividend Yield | 3.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $47.26, up 1.0% on the day, with a bullish technical signal from moving averages. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue reached $6.45B in 2025, though net income margin compressed to 4.61%. Analyst consensus is a $49.33 price target with a mixed buy/hold rating split. Recent news highlights the company's 'Focus to Win' strategy driving North America volume gains and cost savings, alongside ongoing legal challenges.
LW presents a turnaround story with cost-saving initiatives and market share gains supporting upside potential. However, margin pressures, a pending securities lawsuit, and high debt levels pose significant risks. The stock's valuation at a P/E of 21.88 appears reasonable if earnings growth resumes, but investors face headwinds from competitive and operational challenges.
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
